DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/a304c0/pneumococcal_and_m) has announced the addition of the "Pneumococcal and Meningococcal Vaccines: Market Forecast" report to their offering.
Over the next decade, Pfizers Prevnar 13 is set to dominate the pneumococcal vaccine market with sales that could reach $3.4 billion in infants and adults across the US and 5EU by 2019, leaving only marginal roles for its competitors. The commercial opportunity for MenACWY conjugate vaccines will largely remain restricted to the US, while a broad Men B vaccine could achieve blockbuster status.
Scope of the report:
- Detailed sales forecasts for the currently available brands and late-stage pipeline vaccines in the US and 5EU.
- Forecast of key marketed vaccines and late stage pipeline products.
Highlights:
The launch of Pfizers Prevnar 13 for adults is anticipated in 2011 and the vaccine is expected to quickly replace Pneumovax 23 as the gold standard for the primary immunization of elderly and high-risk adults, driving Prevnar 13 to annual sales of $3.4 billion in 2019 across the US and five major EU markets
Sales expectations for conjugate MenACWY vaccines are limited in the seven major markets. While the US are unlikely to recommend routine MenACWY vaccination of infants, MenACWY vaccines will continue to play only a marginal role in Europe, unless a marked serogroup shift occurs. Best growth opportunities lie in a MenB vaccine.
Pneumo- and meningococcal vaccines continue to offer great commercial opportunities, due to changing disease epidemiology and the need for broader age indications. Novartis 4CMenB is the most promising pipeline vaccine and expected to reach blockbuster status with possible sales of almost $3 billion in the US and the five major European markets.
Reasons to buy:
- Obtain full country and product-specific forecasts of currently marketed and pipeline pneumo- and meningococcal vaccines from 2010 to 2019.
- Identify the market dynamics of pneumo- and meningococcal vaccines and the commercial potential of late stage pipeline.
For more information visit http://www.researchandmarkets.com/research/a304c0/pneumococcal_and_m
Source: Datamonitor